We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-9.55%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$541M
AUM Growth
+$81.3M
Cap. Flow
+$124M
Cap. Flow %
23%
Top 10 Hldgs %
62%
Holding
53
New
14
Increased
8
Reduced
19
Closed
9

Top Buys

1
AMRN
Amarin Corp
AMRN
+$22.3M
2
XENT
Intersect ENT, Inc
XENT
+$14.2M
3
VRAY
ViewRay, Inc.
VRAY
+$12.6M
4
WMGI
Wright Medical Group Inc
WMGI
+$11.7M
5
ABBV icon
AbbVie
ABBV
+$10.6M

Top Sells

1
PETX
Aratana Therapeutics, Inc.
PETX
+$37.5M
2
NVRO
NEVRO CORP.
NVRO
+$25.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$10.3M
4
CPRX icon
Catalyst Pharmaceutical
CPRX
+$10M
5
ZGNX
Zogenix, Inc.
ZGNX
+$9.53M

Sector Composition

1 Healthcare 53.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$131M 24.14%
+440,000
New +$130M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$53.4M 9.87%
+700,000
New +$58.2M
AMRN
3
Amarin Corp
AMRN
$292M
$23.8M 4.4%
78,451
+63,901
+439% +$22.3M
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$22.2M 4.11%
532,591
-144,288
-21% -$6.1M
BHVN
5
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20.9M 3.86%
500,000
+100,000
+25% +$4.22M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$2.23B
$20.6M 3.81%
1,131,101
-428,198
-27% -$9.47M
BDSI
7
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$18.1M 3.35%
4,300,066
+18,123
+0.4% +$77.4K
AGN
8
DELISTED
Allergan plc
AGN
$16.2M 3%
96,504
-18,300
-16% -$2.98M
MRTX
9
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.6M 2.88%
200,000
– –
EIGR
10
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$14M 2.59%
45,579
-9,626
-17% -$3.13M
XENT
11
DELISTED
Intersect ENT, Inc
XENT
$13.3M 2.45%
+779,134
New +$14.2M
SIEN
12
DELISTED
Sientra, Inc.
SIEN
$13M 2.4%
200,190
+60,190
+43% +$3.83M
NVRO
13
DELISTED
NEVRO CORP.
NVRO
$12.9M 2.39%
150,510
-337,755
-69% -$25.6M
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$12.9M 2.39%
3,102,673
– –
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
$12.8M 2.36%
618,500
+492,100
+389% +$11.7M
ABBV icon
16
AbbVie
ABBV
$450B
$11.7M 2.16%
+154,500
New +$10.6M
SCTL
17
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$10.9M 2.02%
1,101,352
-639,851
-37% -$6.25M
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
$8.7M 1.61%
3,001,361
+2,134,861
+246% +$12.6M
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.59M 1.59%
177,016
-139,603
-44% -$7.28M
PGNX
20
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$8.01M 1.48%
+1,583,925
New +$7.9M
TVTX icon
21
Travere Therapeutics
TVTX
$5.27B
$7.08M 1.31%
610,414
-442,900
-42% -$7.32M
SSKN
22
DELISTED
Strata Skin Sciences
SSKN
$6.27M 1.16%
291,692
-33,970
-10% -$796K
SBBP
23
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.16M 1.14%
2,578,003
+33,164
+1% +$89.1K
XCUR icon
24
Exicure
XCUR
$10.7M
$5.85M 1.08%
+15,413
New +$5.89M
ZGNX
25
DELISTED
Zogenix, Inc.
ZGNX
$5.53M 1.02%
138,037
-206,725
-60% -$9.53M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Broadfin Capital held 53 positions worth $541M, up 18% from $460M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Broadfin Capital deployed $124M of net new capital in Q3 2019, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Intersect ENT, Inc: 779,134 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 78% a quarter earlier.

On the sell side, the largest reduction was NEVRO CORP., an estimated $25.6M trimmed.

  • Broadfin Capital's largest Q3 2019 buy was Intersect ENT, Inc: 779,134 shares worth $13.3M.
  • Broadfin Capital added most to Amarin Corp in Q3 2019, an estimated $22.3M increase.
  • Broadfin Capital's biggest Q3 2019 reduction was NEVRO CORP., cutting an estimated $25.6M.
  • Broadfin Capital fully exited Aratana Therapeutics, Inc. in Q3 2019, selling an estimated $37.5M.
  • Broadfin Capital's ten largest holdings make up 62% of its $541M portfolio in Q3 2019.
  • Broadfin Capital opened 14 new positions and closed 9 in Q3 2019.
  • Broadfin Capital's portfolio value rose 18% quarter-over-quarter to $541M.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.